Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

H3 receptor blockade with GT-2227 increases wakefulness without subsequent hypersomnolence

July 17, 1998

BIBN-99 improves cognition independent of effects on sleep

July 17, 1998

Cambridge NeuroScience and Boehringer Ingelheim end Cerestat collaboration

July 17, 1998

Venlafaxine relieves anxiety; more cost-effective than other antidepressants

July 16, 1998

Lilly team claims metabotropic glutamate receptor antagonists

July 16, 1998

CNS compounds from ADIR that selectively bind to D4 receptors

July 16, 1998

Phase II clinical trial begins for fibromyalgia treatment

July 16, 1998

Risperidone: satellite symposia discuss impact on cognition and behavior

July 16, 1998

Pfizer reports pharmacokinetics of a novel anxiolytic agent - CP-93393

July 16, 1998

M-100907 improves positive and negative symptoms and is well tolerated in schizophrenics

July 15, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...